Marketing between raises has one job, moving the number your next round will judge. Which number depends on the buyer and on how that buyer becomes revenue, so it varies business to business, and a playbook borrowed from a different model produces the wrong evidence on schedule. A million impressions in front of the wrong audience round to zero.
The stakes sit at both ends of the same report. An estimated 2,345 VC-backed companies are on pace to fail in 2026, the highest level in recent history, and over a third of this year’s failures were founded in the zero-interest years, when capital was cheap and patience came with it. The same report shows the winners moving faster than ever. Companies founded in 2022 reached $5.6M in median revenue inside four years, the fastest on record against a historical $2M to $3M. The market is failing more companies and growing its winners faster at the same time, and focus is what separates the piles.
The bar moved at every stage
The revenue expected at each raise climbed across the board. Companies raising seed rounds in 2025 came in with roughly $363K in revenue, up from $156K in 2021, per SVB. The Series A median went from about $1M in 2021 to $2.8M in 2025, per SVB data via Carta, and Series B moved from $5.8M to $7.1M over the same stretch.
The clock stretched with it. Only 13% of Series A companies raised a Series B within 24 months, and in fintech the median road from seed to A now runs 971 days, per Carta, roughly a quarter longer than the market as a whole. Whatever evidence your next round wants, you will be building it for two to three years. Deciding early what that evidence is costs nothing and buys the whole window.
The path to the dollar comes first
Getting there is part art, part science, and all of it starts with focus. Focus means two answers written down before any channel decision. Who is the buyer, and how does their money become your revenue. Seat-based, usage-based, and transaction-based companies grow different numbers, so the same playbook produces evidence for one and noise for another. In a marketplace, GMV is volume and revenue is the share the platform takes, and volume impresses exactly nobody until the path from one to the other is visible.
The free-user bet shows how much the right number depends on the model. Social platforms grow users and engagement for years before revenue because the audience is the product, monetized later through ads and access to the people they gathered. Bottom-up tools land free inside one team and sell the company once it already depends on them. Slack’s own S-1 describes free teams upgrading as they engage and self-service users feeding the enterprise sales motion. In both models the user base doubles as the research. Usage data shows what the audience wants next, the product gets built toward it, and that flywheel is what investors are actually funding.
Sales-led B2B closes both of those doors. The deal runs through procurement, compliance review, and implementation, and only about 5% of freemium signups ever convert to paid, per OpenView’s 2022 Product Benchmarks report. Here the early signal is customers paying. Ten paying customers watched closely teach you more than ten thousand free signups you never instrument. What they use, what they renew, and why they bought is the data, and it feeds the product, the roadmap, and the messaging the same way usage data feeds a platform.
The pressure runs the other way. Every channel has a vendor, a conference, and a feed telling you you’re already behind, and the spend spreads channel by channel, each one defensible alone, until nothing has enough behind it to prove anything. The fix is a written roadmap that works backward from the next round’s evidence. One channel proven at a time, the sequence behind it, and the part nobody writes down, what you are skipping this year. A roadmap that only lists activities is a wish list.
Seed asks whether the path exists
Seed is the founder’s round. Seed investors evaluate founders while Series A investors evaluate companies, as CRV puts it, and in regulated categories the weighting has sharpened. Rock Health’s H1 2026 review puts founder-market fit near the top of what gets funded, quoting investor Sean Doolan on founders “who understand not just the business function they’re trying to improve, but also the culture and conditions that shape how their customers operate.”
The numbers investors read are small and diagnostic. CRV calls retention the single most telling seed metric and looks for $500K to $1.5M in ARR for a strong B2B SaaS seed, with one channel working rather than five experiments running.
So marketing at seed is founder amplification and narrowing. Build the founder’s profile through PR, bylines, and speaking, because the founder is what’s being bought. Sell the vision to investors and early buyers in the same breath. Narrow to the buyers already paying or closest to it, build the messaging from why they bought, and make the first customer stories the main proof asset. Measure retention, conversion to paid, and buying reasons. Hold the brand campaigns and broad paid media until the base they amplify exists.
Series A asks whether it repeats
At the A, the company has to carry the story the founder carried alone, and the bar is that $2.8M median. The motion changes underneath it. Bessemer marks the run from $1M to $10M ARR as the move from founder-led to sales-led selling, and efficiency starts being read directly, with the burn multiple expected to fall toward 2 after the A.
Marketing’s job is converting founder instinct into a system. Find the one or two channels that convert on repeat and put the budget there. Turn what the founder knows into a playbook, positioning, ICP, and sales enablement. Instrument the CRM and attribution so CAC by channel is a number you can defend, which is its own discipline. Build demand generation on the message the first customers already validated, map the expansion path from individual to team to firm and market to it, and in regulated categories, plan compliance review time into every launch, because the buying committee was already going to be slow.
Series B asks whether it scales
By the B, sales efficiency is capital efficiency. Bessemer’s 2021 benchmarks put CAC payback targets at under 12 months for SMB, 18 for mid-market, and 24 for enterprise, and its GTM guidance targets $8 to $10 of pipeline for every marketing dollar. The round itself got rarer. Digital health saw 30 Series B raises through Q3 2025 against a typical 60-plus per year, the median road from A to B stretched to 27 months from 17 the two years prior, and unlabeled rounds made up 35% of financings through Q3, per Rock Health.
Marketing at this stage scales what’s proven. Grow the channels with receipts and add adjacent segments one at a time. Tie pipeline targets to bookings and report payback to the board in the board’s language. Put real weight behind customer and expansion marketing, because net revenue retention is the efficiency number everyone upstream reads. Brand investment finally becomes defensible, now that there is a base to amplify. And build the marketing ops muscle, forecasting and channel efficiency reporting, because at the B the reporting is the product the board is buying.
Your next round is already reading your marketing.
